{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:31:47Z","timestamp":1791156707092,"version":"4.1.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T00:00:00Z","timestamp":1172102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,2,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Preoperative systemic chemotherapy is increasingly used in patients who undergo hepatic resection for colorectal liver metastases (CLM). Although chemotherapy-related hepatic injury has been reported, the incidence and the effect of such injury on patient outcome remain ill defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review of relevant studies published before May 2006 was performed. Studies that reported on liver injury associated with preoperative chemotherapy for CLM were identified and data on chemotherapy-specific liver injury and patient outcome following hepatic resection were synthesized and tabulated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Hepatic steatosis, a mild manifestation of non-alcoholic fatty liver disease (NAFLD), may occur after treatment with 5-fluorouracil and is associated with increased postoperative morbidity. Non-alcoholic steatohepatitis, a serious complication of NAFLD that includes inflammation and hepatocyte damage, can occur after treatment with irinotecan, especially in obese patients. Irinotecan-associated steatohepatitis can affect hepatic reserve and increase morbidity and mortality after hepatectomy. Hepatic sinusoidal obstruction syndrome can occur in patients treated with oxaliplatin, but does not appear to be associated with an increased risk of perioperative death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Preoperative chemotherapy for CLM induces regimen-specific hepatic changes that can affect patient outcome. Both response rate and toxicity should be considered when selecting preoperative chemotherapy in patients with CLM.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bjs.5719","type":"journal-article","created":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T16:20:26Z","timestamp":1172161226000},"page":"274-286","source":"Crossref","is-referenced-by-count":447,"title":["Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases"],"prefix":"10.1093","volume":"94","author":[{"given":"D","family":"Zorzi","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Laurent","sequence":"additional","affiliation":[{"name":"Laboratoire d'Immunologie and Laboratoire de Recherche Chirurgicale, Unit\u00e9 Propre de Recherche de l'Enseignement Sup\u00e9rieur, 1833 Facult\u00e9 Cochin, Universit\u00e9 Paris V, Paris, France"},{"name":"Service de Chirurgie Visc\u00e9rale et Digestive, Centre Hospitalier Universitaire Henri-Mondor, Universit\u00e9 Paris XII, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T M","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Y","family":"Lauwers","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-N","family":"Vauthey","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E K","family":"Abdalla","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,2,22]]},"reference":[{"key":"2021070911134614700_bib1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/01.sla.0000128305.90650.71","article-title":"Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection\/ablation for colorectal liver metastases","volume":"239","author":"Abdalla","year":"2004","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","article-title":"Trends in long-term survival following liver resection for hepatic colorectal metastases","volume":"235","author":"Choti","year":"2002","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.sla.0000138076.72547.b1","article-title":"Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET)","volume":"240","author":"Fernandez","year":"2004","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/01.sla.0000160703.75808.7d","article-title":"Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases","volume":"241","author":"Pawlik","year":"2005","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00000658-198908000-00001","article-title":"Resection of hepatic metastases from colorectal cancer. Biologic perspective","volume":"210","author":"Steele","year":"1989","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/bjs.1800800302","article-title":"Hepatectomy for liver metastases","volume":"80","author":"Scheele","year":"1993","journal-title":"Br J Surg"},{"key":"2021070911134614700_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00316981","article-title":"Resection of colorectal liver metastases","volume":"19","author":"Scheele","year":"1995","journal-title":"World J Surg"},{"key":"2021070911134614700_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00000658-199610000-00009","article-title":"Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy","volume":"224","author":"Bismuth","year":"1996","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"2021070911134614700_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","article-title":"Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy","volume":"350","author":"Levi","year":"1997","journal-title":"Lancet"},{"key":"2021070911134614700_bib11","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021070911134614700_bib12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"2021070911134614700_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021070911134614700_bib14","doi-asserted-by":"crossref","first-page":"254s","DOI":"10.1200\/jco.2005.23.16_suppl.3535","article-title":"Cetuximab in combination with oxaliplatin\/5-fluorouracil (5-FU)\/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. ASCO Annual Meeting Proceedings","volume":"23","author":"Diaz Rubio","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18S","key":"2021070911134614700_bib15","first-page":"165s","article-title":"Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC)","volume":"24","author":"Hoff","year":"2006","journal-title":"ASCO Annual Meeting Proceedings"},{"key":"2021070911134614700_bib16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib17","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/01.sla.0000145964.08365.01","article-title":"Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archsurg.137.6.675","article-title":"Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization","volume":"137","author":"Abdalla","year":"2002","journal-title":"Arch Surg"},{"key":"2021070911134614700_bib19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/01.sla.0000145965.86383.89","article-title":"A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases","volume":"240","author":"Jaeck","year":"2004","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib20","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.gassur.2003.08.005","article-title":"Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy","volume":"7","author":"Parikh","year":"2003","journal-title":"J Gastrointest Surg"},{"key":"2021070911134614700_bib21","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","article-title":"Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases","volume":"24","author":"Vauthey","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021070911134614700_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1705004","article-title":"GI complications in pediatric patients post-BMT","volume":"36","author":"Barker","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2021070911134614700_bib23","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/00042737-200412000-00019","article-title":"Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation","volume":"16","author":"El-Sayed","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2021070911134614700_bib24","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/00043426-200212000-00013","article-title":"Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients","volume":"24","author":"Reiss","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021070911134614700_bib25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"key":"2021070911134614700_bib26","first-page":"27","article-title":"Nonalcoholic fatty liver disease (NAFLD): a comprehensive review","volume":"36","author":"Salt","year":"2004","journal-title":"J Insur Med"},{"key":"2021070911134614700_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"2021070911134614700_bib28","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7326\/0003-4819-143-10-200511150-00009","article-title":"The metabolic syndrome as a predictor of nonalcoholic fatty liver disease","volume":"143","author":"Hamaguchi","year":"2005","journal-title":"Ann Intern Med"},{"key":"2021070911134614700_bib29","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/gast.2002.33573","article-title":"Nonalcoholic fatty liver disease","volume":"122","author":"Clark","year":"2002","journal-title":"Gastroenterology"},{"key":"2021070911134614700_bib30","first-page":"23","volume-title":"Fatty Liver Disease: NASH and Related Disorders","author":"McCullough","year":"2005"},{"key":"2021070911134614700_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004836-200203000-00013","article-title":"Update on nonalcoholic fatty liver disease","volume":"34","author":"McCullough","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"2021070911134614700_bib32","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1046\/j.1440-1746.2002.02881.x","article-title":"Non-alcoholic fatty liver disease: an overview","volume":"17","author":"Mulhall","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"2021070911134614700_bib33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cld.2004.04.004","article-title":"The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease","volume":"8","author":"McCullough","year":"2004","journal-title":"Clin Liver Dis"},{"key":"2021070911134614700_bib34","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/jhep.2003.50193","article-title":"Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference","volume":"37","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"2021070911134614700_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"2021070911134614700_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"2021070911134614700_bib37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"2021070911134614700_bib38","doi-asserted-by":"crossref","first-page":"S385","DOI":"10.1046\/j.1440-1746.17.s3.32.x","article-title":"Treatment of non-alcoholic fatty liver disease","volume":"17","author":"Sanyal","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"2021070911134614700_bib39","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1002\/lt.20033","article-title":"Obesity and diabetes as a risk factor for hepatocellular carcinoma","volume":"10","author":"Regimbeau","year":"2004","journal-title":"Liver Transpl"},{"key":"2021070911134614700_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2004-823098","article-title":"Nonalcoholic steatohepatitis","volume":"24","author":"Brunt","year":"2004","journal-title":"Semin Liver Dis"},{"key":"2021070911134614700_bib41","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"2021070911134614700_bib42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hep.510370203","article-title":"Nonalcoholic steatohepatitis clinical research network","volume":"37","author":"Anon","year":"2003","journal-title":"Hepatology"},{"key":"2021070911134614700_bib43","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"2021070911134614700_bib44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00000421-199004000-00013","article-title":"Fatty liver change as a result of hepatic artery infusion chemotherapy","volume":"13","author":"Zeiss","year":"1990","journal-title":"Am J Clin Oncol"},{"key":"2021070911134614700_bib45","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/bjc.1998.333","article-title":"Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer","volume":"77","author":"Peppercorn","year":"1998","journal-title":"Br J Cancer"},{"key":"2021070911134614700_bib46","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/1097-0142(19950515)75:10<2592::AID-CNCR2820751029>3.0.CO;2-G","article-title":"Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil","volume":"75","author":"Sorensen","year":"1995","journal-title":"Cancer"},{"key":"2021070911134614700_bib47","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.1993.11.12.2386","article-title":"Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy","volume":"11","author":"Moertel","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021070911134614700_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.500060117","article-title":"Right lobe living donor liver transplantation: a review","volume":"6","author":"Marcos","year":"2000","journal-title":"Liver Transpl"},{"key":"2021070911134614700_bib49","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1091-255X(98)80025-5","article-title":"Hepatic steatosis as a potential risk factor for major hepatic resection","volume":"2","author":"Behrns","year":"1998","journal-title":"J Gastrointest Surg"},{"key":"2021070911134614700_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1072-7515(00)00261-1","article-title":"Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection","volume":"191","author":"Belghiti","year":"2000","journal-title":"J Am Coll Surg"},{"key":"2021070911134614700_bib51","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.gassur.2003.09.012","article-title":"Impact of steatosis on perioperative outcome following hepatic resection","volume":"7","author":"Kooby","year":"2003","journal-title":"J Gastrointest Surg"},{"key":"2021070911134614700_bib52","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jamcollsurg.2005.01.024","article-title":"Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases","volume":"200","author":"Fernandez","year":"2005","journal-title":"J Am Coll Surg"},{"key":"2021070911134614700_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000193603.26265.c3","article-title":"Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases","volume":"243","author":"Karoui","year":"2006","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib54","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u2018hits\u2019?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"2021070911134614700_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"2021070911134614700_bib56","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/0008-5472.948.65.3","article-title":"Controlling tumor growth by modulating endogenous production of reactive oxygen species","volume":"65","author":"Laurent","year":"2005","journal-title":"Cancer Res"},{"key":"2021070911134614700_bib57","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/jnci\/djj049","article-title":"Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir","volume":"98","author":"Alexandre","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2021070911134614700_bib58","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(01)00020-4","article-title":"Senecio disease, or cirrhosis of the liver due to senecio poisoning","volume":"ii","author":"Wilmont","year":"1920","journal-title":"Lancet"},{"key":"2021070911134614700_bib59","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/pbc.20338","article-title":"Veno-occlusive disease of the liver in a child after chemotherapy for brain tumor","volume":"46","author":"Elli","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"2021070911134614700_bib60","first-page":"843","article-title":"Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma","volume":"26","author":"Sulis","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021070911134614700_bib61","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0016-5085(03)01056-4","article-title":"Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition","volume":"125","author":"Deleve","year":"2003","journal-title":"Gastroenterology"},{"key":"2021070911134614700_bib62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cellbi.2005.10.017","article-title":"Role of the actin cytoskeleton during respiratory burst in chemoattractant-stimulated neutrophils","volume":"30","author":"Bengtsson","year":"2006","journal-title":"Cell Biol Int"},{"issue":"Suppl","key":"2021070911134614700_bib63","first-page":"253s","article-title":"Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. ASCO Annual Meeting Proceedings","volume":"23","author":"Nordlinger","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021070911134614700_bib64","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000658-198508000-00007","article-title":"Sclerosing cholangitis after continuous hepatic artery infusion of FUDR","volume":"202","author":"Kemeny","year":"1985","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib65","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.1992.10.7.1112","article-title":"Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial","volume":"10","author":"Rougier","year":"1992","journal-title":"J Clin Oncol"},{"key":"2021070911134614700_bib66","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(94)90750-1","article-title":"Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases","volume":"344","author":"Allen-Mersh","year":"1994","journal-title":"Lancet"},{"key":"2021070911134614700_bib67","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.2000.18.2.243","article-title":"Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma","volume":"18","author":"Lorenz","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021070911134614700_bib68","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gassur.2004.07.004","article-title":"Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials","volume":"9","author":"Clancy","year":"2005","journal-title":"J Gastrointest Surg"},{"key":"2021070911134614700_bib69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0960-7404(02)00032-4","article-title":"Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials","volume":"11","author":"Skitzki","year":"2002","journal-title":"Surg Oncol"},{"key":"2021070911134614700_bib70","first-page":"177","article-title":"Sclerosing cholangitis after chemotherapy by continuous hepatic intra-arterial infusion of fluorodeoxyuridine","volume":"10","author":"Bergmann","year":"1986","journal-title":"Gastroenterol Clin Biol"},{"key":"2021070911134614700_bib71","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/01.SLA.0000071561.76384.19","article-title":"Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases","volume":"237","author":"Onaitis","year":"2003","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib72","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1053\/ejso.1999.0661","article-title":"Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases","volume":"25","author":"Link","year":"1999","journal-title":"Eur J Surg Oncol"},{"key":"2021070911134614700_bib73","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00000658-198712000-00001","article-title":"A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases","volume":"206","author":"Chang","year":"1987","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib74","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.1989.7.11.1646","article-title":"A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial","volume":"7","author":"Hohn","year":"1989","journal-title":"J Clin Oncol"},{"key":"2021070911134614700_bib75","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/1097-0142(19860815)58:4<855::AID-CNCR2820580409>3.0.CO;2-6","article-title":"Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR","volume":"58","author":"Doria","year":"1986","journal-title":"Cancer"},{"key":"2021070911134614700_bib76","first-page":"213","article-title":"Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors","volume":"180","author":"Elias","year":"1995","journal-title":"J Am Coll Surg"},{"key":"2021070911134614700_bib77","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s10434-000-0490-2","article-title":"Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy","volume":"7","author":"Meric","year":"2000","journal-title":"Ann Surg Oncol"},{"key":"2021070911134614700_bib78","first-page":"771","article-title":"The Whisenant\/Venook article reviewed","volume":"18","author":"Abdalla","year":"2004","journal-title":"Oncology"},{"key":"2021070911134614700_bib79","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3816\/CCC.2005.n.043","article-title":"Cancer and Leukemia Group B\/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma","volume":"5","author":"Venook","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"2021070911134614700_bib80","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/01.sla.0000124385.83887.d5","article-title":"Is extended hepatectomy for hepatobiliary malignancy justified?","volume":"239","author":"Vauthey","year":"2004","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib81","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/00000658-200011000-00008","article-title":"Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver","volume":"232","author":"Azoulay","year":"2000","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib82","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1067\/msy.2002.120234","article-title":"Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival","volume":"131","author":"Elias","year":"2002","journal-title":"Surgery"},{"key":"2021070911134614700_bib83","first-page":"1176","article-title":"Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors","volume":"26","author":"Kubota","year":"1997","journal-title":"Hepatology"},{"key":"2021070911134614700_bib84","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/01.SLA.0000048447.16651.7B","article-title":"Portal vein embolization before right hepatectomy: prospective clinical trial","volume":"237","author":"Farges","year":"2003","journal-title":"Ann Surg"},{"key":"2021070911134614700_bib85","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.gassur.2005.09.001","article-title":"Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction","volume":"10","author":"Goere","year":"2006","journal-title":"J Gastrointest Surg"},{"key":"2021070911134614700_bib86","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1245\/s10434-006-9045-5","article-title":"Improving resectability of hepatic colorectal metastases: expert consensus statement","volume":"13","author":"Abdalla","year":"2006","journal-title":"Ann Surg Oncol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.5719","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/94\/3\/274\/36686835\/bjs5719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/94\/3\/274\/36686835\/bjs5719.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T01:11:51Z","timestamp":1736817111000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/94\/3\/274\/6142751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,22]]},"references-count":86,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2007,2,22]]},"published-print":{"date-parts":[[2007,2,22]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.5719","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,3]]},"published":{"date-parts":[[2007,2,22]]}}}